Drug Profile
CT 041
Alternative Names: 1-3 CT041 autologous CAR T-cell injection infusion; Anti-Claudin18.2-CAR-T cell therapy - CARsgen; CAR-CLD18 T cell therapy - CARsgen; CAR-CLDN18.2 T-Cells; Chimeric Antigen Receptor T cells targeting Claudin18.2; Claudin 18.2-CAR-T cell therapy - CARsgen; Claudin18.2 (CLDN18.2) CAR-T - CARsgen; Claudin18.2-redirected Autologous Cells - CARsgen; CLD18-CAR-T cell therapy - CARsgen; CLDN18.2 targeting CAR-T cell therapy - CARsgen; CT-041; CT041 autologous CAR T-cell injectionLatest Information Update: 23 Jan 2024
Price :
$50
*
At a glance
- Originator CARsgen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Gastric cancer; Oesophageal cancer; Pancreatic cancer
Most Recent Events
- 18 Jan 2024 Updated efficacy and adverse events data from a phase Ib/II trial in Pancreatic cancer and Gastric cancer presented at Gastrointestinal Cancers Symposium 2024 (ASCO-GCS-2024)
- 21 Aug 2023 CARsgen and Moderna Therapeutics enters into a collaboration agreement to investigate CT 041 in combination with Moderna's mRNA cancer vaccine
- 11 Jul 2023 Phase-I clinical trials in Pancreatic cancer (Adjuvant therapy) in China (IV) (NCT05911217)